NCT05218759 is a NA clinical trial of Anlotinib in Non-Small Cell Lung Cancer, sponsored by Shanghai Chest Hospital.

Who is sponsoring NCT05218759?

NCT05218759 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT05218759?

Interventions in NCT05218759: Anlotinib.

What condition does NCT05218759 study?

NCT05218759 studies Non-Small Cell Lung Cancer.

Is NCT05218759 still recruiting?

NCT05218759 is currently status unknown. Last updated 1 February 2022.

Last reviewed 2022-02-01 · How we verify

NCT05218759

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Status unknown NA Last updated 1 February 2022

What this trial tests

NA trial testing Anlotinib in Non-Small Cell Lung Cancer in 30 participants. Status unknown.

Timeline

21 February 2022

Primary endpoint
31 May 2025

31 October 2025

Quick facts

Lead sponsor	Shanghai Chest Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	21 February 2022
Primary completion	31 May 2025
Estimated completion	31 October 2025

Drugs / interventions tested

Anlotinib — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Shanghai Chest Hospital

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exosomes detection for the prediction of the efficacy and adverse reactions of Anlotinib in patients with advanced NSCLC

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small extracellular vesicles isolation and separation: Current techniques, pending questions and clinical applications.
Jia Y, Yu L, Ma T, Xu W, et al · · 2022 · cited 229× · PMID 36185597 · DOI 10.7150/thno.74305
Extracellular vesicles: A dive into their role in the tumor microenvironment and cancer progression.
Lopez K, Lai SWT, Lopez Gonzalez EJ, Dávila RG, et al · · 2023 · cited 49× · PMID 37025182 · DOI 10.3389/fcell.2023.1154576
Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709
Exosomes: Insights and therapeutic applications in cancer.
Panigrahi AR, Srinivas L, Panda J. · · 2022 · cited 27× · PMID 35551002 · DOI 10.1016/j.tranon.2022.101439
Exosome therapeutics for non-small cell lung cancer tumorigenesis.
Orooji N, Fadaee M, Kazemi T, Yousefi B. · · 2024 · cited 23× · PMID 39478574 · DOI 10.1186/s12935-024-03544-6
The biological function of tumor-derived extracellular vesicles on metabolism.
Fu X, Song J, Yan W, Downs BM, et al · · 2023 · cited 22× · PMID 37349803 · DOI 10.1186/s12964-023-01111-6
Exosomes and solid cancer therapy: where are we now?
Zemanek T, Danisovic L, Nicodemou A. · · 2025 · cited 15× · PMID 39961904 · DOI 10.1007/s12032-025-02626-3
An update in the applications of exosomes in cancer theranostics: from research to clinical trials.
Shahraki K, Boroumand PG, Lotfi H, Radnia F, et al · · 2023 · cited 15× · PMID 37010586 · DOI 10.1007/s00432-023-04701-6

Verify or expand the search:

Other trials of Anlotinib

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05218759 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 1 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05218759.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing